Enoxaparin in Acute Ischemic Stroke
Therapeutic enoxaparin is NOT indicated for acute ischemic stroke itself—it is only used for venous thromboembolism (VTE) prophylaxis in immobilized stroke patients, not as treatment for the stroke. The evidence provided addresses enoxaparin primarily in acute coronary syndromes, not stroke treatment.
Critical Distinction: VTE Prophylaxis vs. Stroke Treatment
The question asks about "therapeutic enoxaparin" in acute ischemic stroke, but this reflects a fundamental misunderstanding. Enoxaparin serves two completely different roles:
VTE Prophylaxis (The Actual Indication)
For immobilized acute ischemic stroke patients at high risk of VTE, enoxaparin 40 mg subcutaneously once daily is recommended 1. This is prophylactic dosing, not therapeutic.
- Start immediately if no contraindication (e.g., intracranial hemorrhage)
- High-risk patients include those unable to move lower limbs, unable to mobilize independently, or with prior VTE history
- Dose adjustment: Use unfractionated heparin instead if creatinine clearance <30 mL/min 1
- Continue until patient becomes independently mobile or up to 30 days 1
The PREVAIL study demonstrated enoxaparin 40 mg once daily was superior to unfractionated heparin 5000 U every 12 hours for VTE prevention in immobilized stroke patients, reducing VTE risk by 43% (10% vs 18%, p=0.0001) without increasing symptomatic intracranial hemorrhage 2. Long-term neurological outcomes were equivalent between groups 3.
Therapeutic Anticoagulation (Different Context)
Therapeutic-dose enoxaparin (1 mg/kg subcutaneously every 12 hours) is NOT routinely indicated for acute ischemic stroke treatment. The evidence shows:
- Small studies like TRACE used therapeutic enoxaparin 1 mg/kg twice daily in stroke patients with cardiac embolism sources or high-grade stenosis, but this was for secondary prevention in highly selected patients 4
- Avoid antithrombotic therapy within 24 hours after IV alteplase unless compelling indications exist for other conditions 5
- For stroke patients with atrial fibrillation requiring anticoagulation, direct oral anticoagulants (DOACs) are preferred over enoxaparin, initiated early (within 4 days for minor-moderate stroke) 6, 7
Common Pitfalls to Avoid
- Do not confuse prophylactic with therapeutic dosing: 40 mg daily is prophylaxis; 1 mg/kg twice daily is therapeutic
- Do not use therapeutic enoxaparin routinely for stroke: This is not standard care and lacks guideline support
- Do not start any anticoagulation within 24 hours of thrombolysis unless extraordinary circumstances exist 5
- Do not use fixed 40 mg dosing in extremes of weight: Consider anti-Xa monitoring in underweight or overweight patients 8, 9
- Do not use enoxaparin if CrCl <30 mL/min: Switch to unfractionated heparin 1
When Therapeutic Anticoagulation IS Indicated
If a stroke patient has a separate indication requiring therapeutic anticoagulation (e.g., acute coronary syndrome, mechanical heart valve), the dosing follows ACS guidelines 10, 11, 10:
- 1 mg/kg subcutaneously every 12 hours
- Reduce to 1 mg/kg once daily if CrCl <30 mL/min
- For patients ≥75 years with fibrinolytic therapy: 0.75 mg/kg every 12 hours without IV bolus 10, 11
However, this scenario is rare and requires careful risk-benefit assessment given the competing bleeding and thrombotic risks in acute stroke.